- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Molecular epidemiology.
Displaying page 1 of 1.
EudraCT Number: 2011-004518-40 | Sponsor Protocol Number: PCV13-HIV2011 | Start Date*: 2011-10-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: Serological response to antipneumococcal vaccination and consequent impact on Streptococcus pneumoniae nasal carriage in HIV positive adults: a prospective study using 13-valent conjugate vaccine | |||||||||||||
Medical condition: HIV positive adults with out previous PPV23 or PCV7 vaccination | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016566-82 | Sponsor Protocol Number: 05/SP/120 | Start Date*: 2009-12-29 |
Sponsor Name:Belfast Health and Social Care Trust [...] | ||
Full Title: Skin bacteria as a source of surgical infections: molecular epidemiology and prevention of wound contaimination | ||
Medical condition: No medical condition under investigation, investigation of surgical wound contamination in spinal patients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005583-25 | Sponsor Protocol Number: COLIMERO | Start Date*: 2014-07-16 |
Sponsor Name:Consorci Parc de Salut Mar de Barcelona | ||
Full Title: Multicenter, randomized, open label, controlled clinical trial that compares the efficacy of the combination of colistin and meropenem versus monotherapy for the treatment of bacteremia and pneumon... | ||
Medical condition: Bacteriemia and Pneumonia due to Pseudomonas aeruginosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000825-18 | Sponsor Protocol Number: CSET2020/3047 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed p... | |||||||||||||
Medical condition: Relapsed platinum sensitive ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007018-39 | Sponsor Protocol Number: Persephone | Start Date*: 2007-08-09 |
Sponsor Name:Cambridge Hospitals NHS Foundation Trust and Cambridge University | ||
Full Title: Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve | ||
Medical condition: HER2 positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003951-44 | Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 | Start Date*: 2017-12-15 | |||||||||||
Sponsor Name:Hellenic Society of Hematology | |||||||||||||
Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M... | |||||||||||||
Medical condition: Relapsed and /or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005256-97 | Sponsor Protocol Number: SGI-110-06 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) ES (Completed) GB (Completed) FR (Completed) PL (Completed) SE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004699-31 | Sponsor Protocol Number: I3O-MC-JSBF | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
Medical condition: Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003560-31 | Sponsor Protocol Number: UKM18_0021 | Start Date*: 2020-01-29 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
Medical condition: diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000561-33 | Sponsor Protocol Number: TOL-2 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:TolerogenixX GmbH | |||||||||||||
Full Title: An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-ca... | |||||||||||||
Medical condition: Living donor kidney transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005257-12 | Sponsor Protocol Number: SGI-110-07 | Start Date*: 2017-03-17 | ||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Prev... | ||||||||||||||||||
Medical condition: Myelodysplastic syndromes (MDS) Chronic myelomonocytic leukemia (CMML) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) DK (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005010-19 | Sponsor Protocol Number: MPD-RC114 | Start Date*: 2014-11-25 | |||||||||||
Sponsor Name:Consorzio Mario Negri Sud | |||||||||||||
Full Title: Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis | |||||||||||||
Medical condition: Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
